Novo Nordisk's (NOVOB.DK) shares dip about 16% due to the company lowering its full-year 2025 sales and operating profit outlook. Previously, investors had higher expectations for Novo Nordisk’s growth rates, but the updated guidance now forecasts sales growth in the 8–14% range for the year, which is below earlier projections (13-21%).
Today’s moves are largely due to weaker-than-expected Wegovy sales in the U.S. obesity market. The updated sales outlook specifically cites reduced growth expectations for Wegovy in the U.S., as well as slower-than-expected market expansion and stronger competition, particularly from Eli Lilly's rival drug Zepbound.
NOVOB shares are back at multi-year lows after cutting forecast. Source: xStation
Daily Summary: Nvidia drives the Nasdaq 100 up 1.3% (27.08.2026)
US Open: Nvidia breaks the curse – 7% gain drives the Nasdaq! (27.08.2026)
Stock of the week: NVIDIA: The Best Company in the World?
Semiconductor stocks show a muted reaction to Nvidia’s report